Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant

被引:59
作者
Sharma, Vineet [1 ]
Rai, Himanshu [2 ]
Gautam, Dev N. S. [1 ]
Prajapati, Pradeep K. [3 ]
Sharma, Rohit [1 ]
机构
[1] Banaras Hindu Univ, Fac Ayurveda, Inst Med Sci, Dept Rasa Shastra & Bhaishajya Kalpana, Varanasi 221005, Uttar Pradesh, India
[2] Banaras Hindu Univ, DST Ctr Interdisciplinary Math Sci, Inst Sci, Varanasi, Uttar Pradesh, India
[3] All India Inst Ayurveda, Dept Rasa Shastra & Bhaishajya Kalpana, New Delhi, India
关键词
B; 1; 529; variant; COVID-19; Omicron; SARS-Cov-2; coronavirus; transmission rate; COVID-19; MUTATIONS;
D O I
10.1002/jmv.27626
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
COVID's Omicron variant has sparked a slew of concerns across the globe. This review aims to provide a brief overview of what we know about the Omicron variant right now. The new variant has been discovered in 149 countries across all six World Health Organization (WHO) regions since its discovery in South Africa on November 24, 2021 and became the dominant variant in the country in less than 3 weeks. The WHO has warned that the B.1.1.529 variant is spreading at an unprecedented rate, and has urged countries to prepare for the worst. Over the course of this time, researchers from Africa and around the world have uncovered a wealth of information about the virus's epidemiology and biological properties. Case numbers are increasing exponentially in hard-hit areas such as South Africa, United Kingdom, and USA (overtaking the delta variant), implying that the variant is highly transmissible. Initial research has provided some insights into the efficacy of vaccines against the Omicron variant and whether it produces major illness, however, much remains unknown, and additional work is needed to investigate what the initial reports represent in real-world situations.
引用
收藏
页码:1876 / 1885
页数:10
相关论文
共 91 条
[1]   Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants [J].
Abu-Raddad, Laith J. ;
Chemaitelly, Hiam ;
Butt, Adeel A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02) :187-189
[2]  
Ali Fedaa, 2021, Med Drug Discov, V10, P100086, DOI 10.1016/j.medidd.2021.100086
[3]  
[Anonymous], 2021, SCI BRIEF OM B 1 1 5
[4]  
[Anonymous], SARS COV 2 VAR VAR I
[5]  
[Anonymous], 2021, UPD OM
[6]  
[Anonymous], 2021, TRACK VAR
[7]  
Bai Yuan, 2021, medRxiv, DOI 10.1101/2021.12.07.21267410
[8]  
Barnard RC., 2021, PROJECTED EPIDEMIOLO, DOI [10.1101/2021.12.15.21267858v1, DOI 10.1101/2021.12.15.21267858V1]
[9]   SARS-CoV-2, COVID-19 and the aging immune system [J].
Bartleson, Juliet M. ;
Radenkovic, Dina ;
Covarrubias, Anthony J. ;
Furman, David ;
Winer, Daniel A. ;
Verdin, Eric .
NATURE AGING, 2021, 1 (09) :769-782
[10]   Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant [J].
Bernal, Jamie Lopez ;
Andrews, Nick ;
Gower, Charlotte ;
Gallagher, Eileen ;
Simmons, Ruth ;
Thelwall, Simon ;
Stowe, Julia ;
Tessier, Elise ;
Groves, Natalie ;
Dabrera, Gavin ;
Myers, Richard ;
Campbell, Colin N. J. ;
Amirthalingam, Gayatri ;
Edmunds, Matt ;
Zambon, Maria ;
Brown, Kevin E. ;
Hopkins, Susan ;
Chand, Meera ;
Ramsay, Mary .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) :585-594